Brefeldin A

For research use only.

Catalog No.S7046

19 publications

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Brefeldin A has been cited by 19 publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NG\QenNHfW6ldHnvckBCe3OjeR?= MkLFNkDPxE1? M4jXN|EhcA>? M1vVRolvcGmkaYTzJJRp\SCOLVTPVGEhMDJywrFOwG0qNWmwZIXj[YQhfHKjboPp[Y51KEWUS{GvNkBxcG:|cHjvdplt[XSrb39CpC=> MUmyOlM3OzF7MR?=
C2C12 MmfmSpVv[3Srb36gRZN{[Xl? MmqwNeKh|rypL33s MVmxxsBp M2fJTYFjd2yrc3jld{BkgXSxa3nu[UBz\WynYYPlJIZzd21iQ{LDNVIhdXmxdIXi[ZM> NWfzSYFDOjZ{OUGyO|k>
MEFs WT Mlq0SpVv[3Srb36gRZN{[Xl? MnfGOeKh|ryP MkGyNlAhdWmw M2\ENINifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ? M4rJXlI3OTl4MEKz
MEFs VAMP7 KO M4nrfGZ2dmO2aX;uJGF{e2G7 MVG1xsDPxE1? M2HkVlIxKG2rbh?= M{XiUYNifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ? M4jDOFI3OTl4MEKz
SMCs NF31XYdHfW6ldHnvckBCe3OjeR?= MYSxNOKhyrWpL33s NELuOW0xNTF{IHi= MlLUSG1UVw>? M4Dr[ZNpd3e|IHGgeJJmdmRidH;3ZZJleyCjIHjp[4hmeiClb37j[Y51emG2aX;uJI9nKHSqZTDFVk9UWiCwZYT3c5JsKGmwIITo[UBx\XKrboXjcIVieiCjcnXhxsA> M{j4b|I3OTd{MEiw
SMCs NVzNNFFpTnWwY4Tpc44hSXO|YYm= MonCNVDDqML3Zz;tcC=> NILGUJExNTF{IHi= M3n3PGROW09? Mk\TZ4F2e2W|IHGgeJJidnOrZX70JGNiOiwEoILlcIVie2ViZoLvcUB1cGViRWKvV3LDqA>? NWjn[oRuOjZzN{KwPFA>
HEMC-1 M1nQdmZ2dmO2aX;uJGF{e2G7 NGDoXHkxNjIEoNM1[{9udA>? NGjZRVYzPMLiaB?= NIfF[olk[XW|ZYOgZUBpcWeqZYKgbY5pcWKrdH;yfUBm\m[nY4Sgc44h\XixY4n0c5NqeyC2aHHuJI5w[2:mYYrvcIU> NY\NfWhtOjV7N{K3OVk>
HUVEC M17YfGZ2dmO2aX;uJGF{e2G7 NYnoW3FTOTEEoN88US=> M17lR|HDqGh? NHX1ZmNFVVOR NIrJS3di[m:uaYPo[ZMhcHmyb4jpZU1qdmS3Y3XkJJJmdGWjc3Wgc4YhSVSSIH\yc40h[XCrY3HsJIFv\CCkYYPvcIF1\XKjbDDzeZJn[WOncx?= MXqyOVk2Pjl6OB?=
HUVEC NFvFfWtHfW6ldHnvckBCe3OjeR?= NILFNG4yOMLizszN NXTWdIpEOcLiaB?= M{\3cmROW09? MmTNbY5kemWjc3XzxsB1cGViboXtZoVzKGGwZDDpcpRmdnOrdImgc4Yh\my3b4Lld4NmdnRiYYLlZZMh\XOyZXPpZYxtgSCrbjDw[ZJqdnWlbHXhdkB{eGGlZR?= NWTIW4NkOjV7NU[5PFg>
Caco-2 M{PaVWZ2dmO2aX;uJGF{e2G7 MW[yMlUh|ryP Ml\EN|AhdWmw NF;pUI5ifHSnboXheIV{KHSqZTDUS2Yu|rJzLX3l[IlifGWmIHnuZ5Jm[XOnIHnuJHNGWlRiZoXuZ5Rqd25? NYTLfVM5OjV7NUS5N|E>
NRK MUfGeY5kfGmxbjDBd5NigQ>? MmO5NlAx6oDHbnevcYw> M3TufVTjiIWq MVLEUXNQ NVzoOm1WemW|Y4Xld{BucXSxdHnjJJBzd2e{ZYPzbY9v NID1d5kzPTl2OEW4Oi=>
HeLa M{LHO2Z2dmO2aX;uJGF{e2G7 M4TCeFIxOOLChX7nM41t MVWzJIg> MVXEUXNQ NUHwbVFzcW6mdXPld{B1cGViYYL0bYZq[2mjbDDidoVicy23cDDv[kB1cGViR3;s[4kh[2:vcHzlfC=> NEHGTYEzPTl2OEW4Oi=>
COS MYrGeY5kfGmxbjDBd5NigQ>? M4j0TVEh|rypL33s MX2zJIg> M1\zfoNwdXCuZYTlcJkh\Gm|cHXyd4V{KHSqZTDBVE0yKHOrZ37hcOKh NIW3[XgzPTlzNUmwNC=>
DF1  NE\GOmtHfW6ldHnvckBCe3OjeR?= MWmxxsDPxE4EoB?= NIPkUJc1QCCq NGPHOnZFVVOR M2PjTIRqe3CncoPld:KhfGinIHX4c4dmdm:3czDDV2didE6DY2SyJJBzd3SnaX6= MYeyOVgxPzB3NB?=
nHDFs  MXTGeY5kfGmxbjDBd5NigQ>? NG\yelQyyqEQvF5CpC=> MmLPNuKhcA>? NGe3bZNxemW4ZX70d{B1cGViYYPz[Y1jdHlib3[gZ5l1d3OxbHnjJINw[XRicILveIVqdnNib370c{BId2ypaTDt[Y1jemGwZYO= M1nKeFI2Pzd{NkG2
FRT  NUjkW4FITnWwY4Tpc44hSXO|YYm= MnLCOUDPxGdxbXy= MnexNuKhcA>? NGm3S5VjdG:la4OgeJJi\m[rY3vpcochfGi{b4XnbEB1cGViR3;s[4kh[2:vcHzlfEBjgSCrbnjpZol1cW6pIFXSMZRwNUexbHfpJJRz[W6|cH;yeC=> MYCyOVc3PzFzNR?=
FRT  NYn2O5AzTnWwY4Tpc44hSXO|YYm= NY[2[Zh5PSEQvHevcYw> NVHhNo5FOsLiaB?= MXzwdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iY3zlZZZm\CEQsTDzeYJ2dmm2czD3bIVvKFuQYTvdbeKhf2G|IILl[JVk\WR? M2PCdVI2PzZ5MUG1
HepG2  NXjTdVZkTnWwY4Tpc44hSXO|YYm= Mn6xNgKBkcL3TdMg MW[yOEBp MoL5SG1UVw>? NYHnSWxM\GWlcnXhd4V{KHSqZTDs[ZZmdCCxZjDQXHIhdVKQQR?= NFjhRZIzPTZzNkW5Oy=>
SMCs NVLFTWhNTnWwY4Tpc44hSXO|YYm= MVix{txoN22O MV6zJIg> M{fMT4Fk[3WvdXzheIV{KEOQUGmyJJBzd3SnaX6gbY4hfGinIFXSJINwdXCjcoTt[Y51KGGwZDDuc{Btd26pZYKgZ48udG:lYXzpfoVlKHerdHigeIhmKEexbHfpJI1iemunctMg MmHMNlU2QDl2MkW=
OB-6 MX\BdI9xfG:|aYOgRZN{[Xl? MmDoNk44yqEQvF2= MVq0PEBp MkTXbY5lfWOnczDhdI9xfG:|aYO= M3POSVI2PTN{NEiw
iPSC-CMs  MX\GeY5kfGmxbjDBd5NigQ>? NFjNV402ODBibnevcYw> MXi0PEBp NEH3UmlqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kB1cGViaHnnbIVzKG2xYnnsbZR6KEyDTWDzJIF1KHSqZTDjc5N1KG:oIITo[UBtd3encjDtc4JqdGm2eTDzdIVkcWW| NIXlSpczPTR6OE[2Oi=>
SP-Nluc MmXQSpVv[3Srb36gRZN{[Xl? NHvsRpE2KG2pL33M MlrCOkBp MlHESG1UV8Li NXvvXFBv[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? NWfFXnJKOjV|OUK5PVg>
PEXEL-Nluc MUHGeY5kfGmxbjDBd5NigQ>? MYO1JI1oN22O Mm\DOkBp NUW1e3dMTE2VT9Mg NYLE[o9i[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? NEDGWYszPTN7Mkm5PC=>
H1299 MmrvSpVv[3Srb36gRZN{[Xl? M2LqelExKM7:Zz;tcC=> MnHTNlQhcA>? NFm0WGtqdmS3Y3XzJIF2fG:yaHHnfeKh NWTSeFF{OjV|OEi5O|A>
MDA-MB-231 MlrJR4VtdCCYaXHibYxqfHliQYPzZZk> NIq4TIcx6oDVNUCg{txoN22O NFvLclU1QCCq M3TueWVEPTEEoE2gNE4xOTZiwsXnM41N M2[5bFI2OzV4NU[3
MDA-MB-231 M{\aNGFxd3C2b4Ppd{BCe3OjeR?= NHfWTmkxNjFizsznM41N M1\vb|QhcA>? MVzpcoR2[2W|IHHwc5B1d3Orcx?= MnPONlU{PTZ3Nke=
MDA-MB-231 M4H0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2wNE4xOS9yLkC1JO69\y:vTB?= M3vGe|I1KGh? MlLPbY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDzeYIuTzFiY3XscEBl\WK{aYO= M3HJbFI2OzV4NU[3
MDA-MB-231 MXvBdI9xfG:|aYOgRZN{[Xl? NYCyO4REOC5yNfMAl|Eh|rypL33M NEf2Z2szPCCq MnW5bY5lfWOnczDQRXJRKCiyb3z5JGFFWC2{aXLvd4UheG:ueX3ldoF{\S1zKTDjcIVifmGpZR?= MmHNNlU{PTZ3Nke=
MDA-MB-231 MUfGeY5kfGmxbjDBd5NigQ>? NI\nbpQx6oDVNUCg{txoN22O NWrEbVFwOjRiaB?= M33BOIlvcGmkaYTzJJRp\SCob4LtZZRqd25ib3[gN2Qh[W6mIELEJINwdG:waXXz M1rGeFI2OzV4NU[3
A172 Ml:4SpVv[3Srb36gRZN{[Xl? Mnv5NVDDqM7:Zz;tcC=> MnezOOKhcA>? NIHjVlJFVVORwrC= NEL5RWtz\XO3bITzJIlvKHSqZTDy[ZRzd2e{YXTlJJRz[W6|cH;yeEBw\iCobIXvdoV{[2WwdDDndoFvfWyncx?= NFSxXWkzPTJ|OUWwOy=>
KMS-6 MVTGeY5kfGmxbjDBd5NigQ>? MX:xxsDPxE4EoB?= NY\6dFZsOjRiaB?= NXTBU2lQ\XiqaXLpeJMhcGGuZjD0bIUhe2WlcnX0bY9vKG:oIHfhcIFvcW5vTFmgZZMh\GmmIITo[UBkd262cn;s NUf1XHFxOjV{MkmxNlY>
MEC NES0VItHfW6ldHnvckBCe3OjeR?= M13Yc|Eh|ryP NFX4fG4yNjViaB?= NHrPO|Bk[XW|ZYOgZUBlemGvYYTpZ{Bl\WO{ZXHz[UBqdiC2aHWgd5Vz\mGlZTDWSWdHWjJ? MkSyNlUzOjh6MUW=
HEK293/hERG MXPGeY5kfGmxbjDBd5NigQ>? MVWxNOKh|ryP NXnCfpJSOcLiaB?= NUG0U4duemW|dXz0d{BqdiCjIITpcYUu\GWyZX7k[Y51KHKnZIXjeIlwdiCvYYT1doUhcEWURzDwdo91\WmwwrC= M4LDSlI2OjF6NE[5
RBE4 NH3HTHpCeG:ydH;zbZMhSXO|YYm= MUKyxsDPxE1? M3KwOFPjiJN{NNMgbC=> Mkn4bY5lfWOnczDhdI9xfG:|aYOgeIlu\SCmZYDlcoRmdnSueR?= NWPuNW1GOjVzMkiwNlU>
RBE4 M17RfmZ2dmO2aX;uJGF{e2G7 MVSyxsDPxE1? M2TpUlPjiJN{NNMgbC=> Mn[2bY5kemWjc3XzJJRp\SC[QmCxJJBzd3SnaX6gcIV3\Wy|IHHmeIVzKDNiYX7kJFbDqGhib3[geJJm[XSvZX70 MX6yOVEzQDB{NR?=
RBE4 MmL3SpVv[3Srb36gRZN{[Xl? NHjY[HAzyqEQvF2= MlXwN-KBmzJ2wrDo MXzpcoNz\WG|ZYOgZYN1cX[nIHPhd5Bie2VvMUKgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> MlvHNlUyOjhyMkW=
RBE4 NUnibFJ2TnWwY4Tpc44hSXO|YYm= Mn\JNuKh|ryP MWez5qCUOjUEoHi= NVTne5p2cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVm9UKHSrbXWt[IVx\W6mZX70cJk> NInh[HgzPTF{OECyOS=>
RBE4 NFP4SmRHfW6ldHnvckBCe3OjeR?= NHP2eJczyqEQvF2= M3vrNFPjiJN{NNMgbC=> MnTabY5lfWOnczDhJIRmdGG7ZXSg[IVxdGW2aX;uJI9nKHSqZTDFVkBE[TJtwrDjc451\W62IHH0JFbDqGhib3[gbY5kfWKjdHnvckB{cWewaX\pZ4FvfGy7 NH34cFUzPTF{OECyOS=>
RBE4 NFvXRmJHfW6ldHnvckBCe3OjeR?= MnHQNuKh|ryP M3;hNlPjiJN{NNMgbC=> NYLUXnkycW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= NIG4U5czPTF{OECyOS=>
Huh-7  MkHiSpVv[3Srb36gRZN{[Xl? NXTJWItbOc7:Zz;tUC=> M3\TU|PjiJN{NNMgbC=> MUXpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MW[yOVAzPjF5NB?=
HepG2  MVXGeY5kfGmxbjDBd5NigQ>? MmXaNe69\y:vTB?= NVXJe3A3O+LCk{K0xsBp MVXpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M4HQRVI2ODJ4MUe0
H838-LKB1 MorTSpVv[3Srb36gRZN{[Xl? MmPCN|DDqG6pL33s NYT1TlhZOTJxMUigbC=> NUSxOWJ[cW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? MoLjNlUxOTFyOEK=
H838-KDLKB1  NGnGTY1HfW6ldHnvckBCe3OjeR?= M4e5SVMxyqCwZz;tcC=> NG\qPGIyOi9zODDo MUnpcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKEKrUNMg NV\CS3hiOjVyMUGwPFI>
H838-KDLKB1  M4\2OmZ2dmO2aX;uJGF{e2G7 MmroN|DDqG6pL33s MUSxNk8yQCCq MX7pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyaH;zdIhwenmuYYTl[EBmUUZ{zsGgLJBpd3OyaH:t[WlHOs7zKR?= M1fkSlI2ODFzMEiy
3T3-L1 NFXxe5FHfW6ldHnvckBCe3OjeR?= NYjwV3RzPSEQvHevcYw> NXLXcIN7OzBibXnu Mn:1cYlucWO|IITo[UBm\m[nY4TzJI9nKGmwc4XsbY4h[W6mIHPheZNmeyC{b3L1d5QheGixc4Doc5J6dGG2aX;uJI9nKEGtdDCoV4VzKDR5MzmgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCDU{G2NEApXGi{IE[0NkBidmRiU3XyJFU5QCl? MVWyOFg1Ozh{Nx?=
3T3-L1 NIrzSZZHfW6ldHnvckBCe3OjeR?= M2XBR|Uh|rypL33s MlX4N|AhdWmw NEnR[XNz\WOjcHn0eYxifGW|IHnud5VtcW5iYXP0bY9vKHerdHigdoV{eGWldDD0c{Bz\We3bHH0bY5oKEGtdDDhZ5Rqfmm2eTDhcoQhSVNzNkCgdIhwe3Cqb4L5cIF1cW:w NIK2VZkzPDh2M{iyOy=>
3T3-L1 NVHmVFM1TnWwY4Tpc44hSXO|YYm= NUfwfFlqPSEQvHevcYw> MnnZN|AhdWmw M4XiUINifXOnczDy[ZZmenOrYnzlJJJm\Gm|dILpZpV1cW:wIH;mJGdNXVR2 NELBcW0zPDh2M{iyOy=>
3T3-L1 NYLaVXo{TnWwY4Tpc44hSXO|YYm= NWK1bWgyPSEQvHevcYw> MWCxxsBp NEPJTZlk[XW|ZYOgdoVlcXO2cnnieZRqd25ib3[gS2xWXDRiYoX0JI5wfCCrbnPy[YF{\SCrbjDncJVkd3OnIIXweIFs\Q>? NXj1[ZBsOjR6NEO4Nlc>
3T3-L1 M1;ObmZ2dmO2aX;uJGF{e2G7 NYjUNIgzPSEQvHevcYw> M{XCW|HDqGh? MUDjZZV{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIITo[UBHd3iRMTD0doFve2O{aYD0bY9vKG[jY4Tvdi=> M1HqS|I1QDR|OEK3
HeLa  NYGzdGU5TnWwY4Tpc44hSXO|YYm= Mnr6OUDPxGdxbXy= M1P4WFMhcA>? NXnESod3[2G3c3XzJI52[2ynYYKg[ZhkdHW|aX;uJI9nKHSqZTDGc5hQOSC2cnHud4NzcXC2aX;uJIZi[3SxcjDhcoQh\GWlcnXhd4V{KHS{YX7zZ5JqeHSrb36gc4YhTm:6T{GtdoVofWyjdHXkJIdmdmW| M{PZZ|I1QDR|OEK3
HEK293 M3XrWWZ2dmO2aX;uJGF{e2G7 NVjXe4ZyPcLizsznM41t NFn4dYcyOsLiaB?= MlKxZYJwdGm|aHXzJGNOSS2rbnT1Z4VlKEOURVzENkB{\WO{ZYTpc44> NG\Zd4ozPDZ6N{SzNS=>
COS-1 Mke4SpVv[3Srb36gRZN{[Xl? NYTmW3JTPSEEtXevcYw> NE\QTnYzPCCqwrC= MXTy[ZN1emmldIOgcI9k[WyrenH0bY9vKG:oIF7CJIlvKHSqZTDw[ZJqdnWlbHXhdkBz\Werb39CpC=> NH;ZXWEzPDZ5MUe1NS=>
PRP NX3US5ltTnWwY4Tpc44hSXO|YYm= MmLyNVAh|ryP M1HxbIFjem:pYYTld{BUTEZvMd8xMY1m\GmjdHXkJGNZS1J5IHX4eIVzdmGuaYrheIlwdsLi MnHTNlQ3Pjh5NUC=
RAW264.7 MkTHRZBweHSxc3nzJGF{e2G7 MUC0JO69VQ>? MkToOFghcA>? M2rPSoF1fGWwdXH0[ZMhfGinIHnubIljcXSrb36gc4Yhd3hvTFTMMYlv\HWlZXSgZZBweHSxc3nzJIFv\CC2aHWg[oFkcWyrdHH0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDifUBC[y2qRT2xPGEuVkh{ NGPmZnQzPDZ|OUCzNi=>
MDMs NULVc|BYSXCxcITvd4l{KEG|c3H5 M{XwelEx6oDLzsznM41t M17IXlEzNzF3IHi= MUHpcoR2[2W|IHHwc5B1d3Orcx?= M2TjWlI1PTV4Nkm1
PMHs  NUm4bnBNTnWwY4Tpc44hSXO|YYm= NGPrV3gyOOLCk{Kw5qCK|rypL33s MXWyOQKBkWh? NFnVe4lFVVOR NXLIZpo4cW6mdXPl[EBGWiC|dILld5M> MnHvNlQ1ODd{NEK=
PMHs  NHvDTXpCeG:ydH;zbZMhSXO|YYm= NFnQeXUyOOLCk{Kw5qCK|rypL33s NWjJN2ZJOjUkgJno NW\BS|UxTE2VTx?= MYXpcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> M3vhTlI1PDB5MkSy
HEK293/tau MmL2SpVv[3Srb36gRZN{[Xl? NV7WdIF1PSEQvF2= MYmxM|IwPCCq M3G1VYlv\HWlZYOgS49t\2liZoLh[41mdnSjdHnvcuKh MmG5NlQ{PjhyOEm=
HEK293/tau MoTtSpVv[3Srb36gRZN{[Xl? MVi1JO69VQ>? M{DQdVMhcA>? NUDLPJdIcW6mdXPld{B1[XViaInw[ZJxcG:|cHjvdplt[XSrb36= NV\HNIs{OjR|NkiwPFk>
ADF MmPRSpVv[3Srb36gRZN{[Xl? NYjhVJd6OTBizszN NEfsVJEyPiCq MUPpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> MlfqNlQzOjh{M{K=
U373  MVzGeY5kfGmxbjDBd5NigQ>? NGe4ZZgyOCEQvF2= NFe1U2oyPiCq MVPpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> MlXYNlQzOjh{M{K=
RKO-HIPK2i Ml\1SpVv[3Srb36gRZN{[Xl? NF3WZpcyOCEQvF2= NIHhd5IyPiCq MWrpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> NYnoXlk6OjR{MkiyN|I>
ADF  MWHGeY5kfGmxbjDBd5NigQ>? MUCxNEDPxE4EoB?= Ml3aOkBp Mn74bY1x[Wm{czD0bIUhTENiYXP0bZZifGmxbh?= M4TsTVI1OjJ6MkOy
Huh7 NUTrd2RUTnWwY4Tpc44hSXO|YYm= M4rBZVUh|rypL33s MXW0JIg> NH3YPFNi[m:uaYPo[ZMhfGinIIPlZ5JmfGmxbjDv[kAhcW62cnHj[YxtfWyjcjDBdI9D MWiyOFExODF2MB?=
Huh7 MlHkSpVv[3Srb36gRZN{[Xl? NEXtNJk2KM7:Zz;tcC=> M3;HPVEhcA>? NX3pbo5s[2G3c3XzJIEhe2mpbnnmbYNidnRiaX7jdoVie2ViaX6gRZBwSi2lcnXzZ4VvfHN? MYWyOFExODF2MB?=
Huh7 Mnv3SpVv[3Srb36gRZN{[Xl? NV3PPXN2PeLCk{GwxsBv\y:vbB?= NXzqeJhIOTJiaB?= M1ezRYlv[3KnYYPld{BCeG:ELXPy[ZNk\W62czD3bZRpd3W2IHnubIljcXSrbnegd4VkemW2aX;u NVjOOGJVOjRzMECxOFA>
BAECs NGG4XWVHfW6ldHnvckBCe3OjeR?= M1zSZlUh|rypL33s Mom1NE01KGh? M4\HSYlv\HWlZYOgeIhmKHKjcHnkJIRmeGixc4Doc5J6dGG2aX;uJI9nKGWQT2OgZZQhW2W{MUG3PS=> M3rqTVI1ODh3MkK1
Macrophages M1i2UGZ2dmO2aX;uJGF{e2G7 MUi3NUDDvU1? MX:2JIg> NGHwSpZqdmirYnn0d{BtfW6jc3nuJIlvfGW{bnHsbZpifGmxbtMg M{X4PFI1ODN7N{Sw
Colo 205 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYewMVUh|rypL33M NV;mWmlWPDhiaB?= NF7Te5BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDzeZNx\W6|aX;uJIN2dHS3cnXzJJdqfGhiYX6g[ZN1cW2jdHXkJGlEPTBib3[gglE2KG6pL33M MYGyN|k4Ozl7Nh?=
Colo 205 NVLienRmTnWwY4Tpc44hSXO|YYm= MkPUNE4xOTJvMD6wNlUh|rypL33M MXGxOEBl NXjmNoxKemWmdXPld{B1cGViY3zvco9o\W6rY3n0fUBw\iCFb3zvJFIxPSCFU1Pz NHzFVoQzOzl5M{m5Oi=>
Colo 205 NVfiW4l5SXCxcITvd4l{KEG|c3H5 M1;0dlAvOSEQvHevcWw> MUmwMVI1KGh? M2S5[Ilv\HWlZYOgZZBweHSxc3nzJI9nKEOxbH:gNlA2KGOnbHzzJIlvKHO3c4DlcpNqd25iY4XseJVz\XN? M1jz[FI{QTd|OUm2
Colo 205 MXLGeY5kfGmxbjDBd5NigQ>? NF;Uc|QxNjBzNTFOwIcwdUx? MlKzNlQhcA>? MWLpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFXSJJN1emW|cz3y[YxifGWmIHflcoV{ NVH2dpBHOjN7N{O5PVY>
Colo 205 NGLnU21HfW6ldHnvckBCe3OjeR?= MXuwMlAyPSEQvHevcWw> MoPoNlQhcA>? MYXpcohq[mm2czD0bIUh[WO2aY\peJkhd2ZiTV3Qdy=> NEDWbm8zOzl5M{m5Oi=>
IBRS2 Mmn1SpVv[3Srb36gRZN{[Xl? NH;kVXQ2KM7:Zz;tcC=> NFXTZYcxNjViaB?= Mme4SG1UVw>? Mmfl[Il{enWydIOgeIhmKEWUR1nDJIFv\CCJb3znbeKh NUf4OYJwOjN7NkO1N|Q>
IBRS2 MXLGeY5kfGmxbjDBd5NigQ>? M{LHVFUh|rypL33s MXiwMlUhcA>? MmOySG1UVw>? MmHR[Y5p[W6lZYOgSm1FXiCrbn\lZ5Rqd25? NGP3PGEzOzl4M{WzOC=>
HeLa MYHGeY5kfGmxbjDBd5NigQ>? M1PpeVIh|ryP MnfYNkBpyqB? NH7aT2JifHSnboXheIV{KHSqZTDUUmYucW6mdXPl[EB{\WO{ZYTpc44hd2ZiSVytNVU> MYeyN|k2ODh7Mh?=
HFS  NXXBeJhqTnWwY4Tpc44hSXO|YYm= M4\6V|AuOSEQvHevcYw> MXOyOEBp M4jaPGdNXFBiZYjwdoV{e2mxbjDy[YFkcGW|IHGgdIxifGWjdTDheEBkd26lZX70doF1cW:wczDhd{Btd3diYYOgNE4xOSEEtXevcYw> NF;yWI0zOzh7NE[zNy=>
HFS  Mn7RSpVv[3Srb36gRZN{[Xl? MlTsNE4xOSEEtXevcYw> NEL4bGQzPCCq NGK5OYdqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\2y7Y3;zdIhqdmexbHnwbYQhe3mwdHjhd4Uh\2WwZYOgZZQhPiCq NHnRVVUzOzh7NE[zNy=>
OVCAR-3 NYj5cZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHXNgKBmzF3wrFOwG3DqA>? NHLDdWkzPMLiaB?= M{PSRolv\HWlZYOgZUBtd3O|IH;mJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHoEoB?= NVfVU3JiOjN6Mk[5OlQ>
OVCAR-3 M4[4cmZ2dmO2aX;uJGF{e2G7 NEXPRY8y6oDVMUZCpO69VcLi NXzs[IxzOjUEoHi= NX7yO|l5cW6mdXPld{BvfWOuZXHyJIRidWGpZR?= Mn7qNlM5OjZ7NkS=
OVCAR-3 NFj0boFCeG:ydH;zbZMhSXO|YYm= M4jGd|EuOTEEoN88US=> MXW0JIg> MUnpcoR2[2W|IITo[UBi[3SrdnH0bY9vKG:oIHHwc5B1d3Orcz3y[YxifGWmIIDyc5RmcW6| MXeyN|gzPjl4NB?=
OVCAR-3 MkDqRZBweHSxc3nzJGF{e2G7 M4LLV|ExyqEQvF2= MXOyOOKhcA>? NVviZ4VzcW6mdXPld{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2W| NIPDeHUzOzh{Nkm2OC=>
OVCAR-3 MojMSpVv[3Srb36gRZN{[Xl? NICxbJky6oDVMUFCpO69VQ>? MlP6NlTDqGh? NXq2XXFzcW6mdXPld{BlcXO{dYD0bY9vKG:oIITo[UBucXSxY3jvcoRzcWGuIITyZY5{dWWvYoLhcoUheG:2ZX70bYFt M2GxU|I{QDJ4OU[0
OVCAR-3 M2[yd2Z2dmO2aX;uJGF{e2G7 NILRNVAy6oDVMUFCpO69VQ>? M2nqVlI1yqCq Mn\EbY5lfWOnczDmc5Ju[XSrb36gc4YhemWjY4TpeoUhd3i7Z3XuJJNx\WOrZYO= Ml3hNlM5OjZ7NkS=
OVCAR-3 NHizfI5HfW6ldHnvckBCe3OjeR?= NF:yXFQy6oDVMUFCpO69VQ>? M2H4TFI1yqCq MVPpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= NWPYV3FROjN6Mk[5OlQ>
MKN45 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnyTWM2ODxyLkCwNUDPxGdxbXy= MXGyN|c6OzN2Mh?=
LOVO NW[3N251T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvoTWM2OD1yLkGyJO69\y:vbB?= MlLvNlM4QTN|NEK=
A549 NX7GOFd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMESg{txoN22u MmHkNlM4QTN|NEK=
MDA-MB-435 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInyPXlKSzVyPECuNFAyKM7:Zz;tcC=> NXWyfmhLOjN5OUOzOFI>
HepG2 NYXQfXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRDBwMECxJO69\y:vbB?= M1yzXFI{Pzl|M{Sy
HL-60 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP6TWM2ODxyLkCwNUDPxGdxbXy= NF:4emIzOzd7M{O0Ni=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / GRP78 ; 

PubMed: 22859938     


(B) present the dose- and time- dependent effect of ER stress inducer brefeldin A on p53 expression. MCF-7 Cells were exposed to brefeldin A in 10% FBS–supplemented DMEM as time and dose indicated. The cell lysates were analyzed by western blotting with antibodies for p53, GRP78, and α-tubulin. The p53 protein expression level was quantified densitometrically. GRP78 served as an ER stress marker. 

22859938
Immunofluorescence
MTP / GBF1 ; 

PubMed: 26267806     


3T3-L1 cells, plated as above, were treated with brefeldin A (5 μg/ml, 3 hr), fixed and stained for MTP and GBF1. Brefeldin A treatment leads to redistribution of MTP from the juxtanuclear region, similar to what occurs with GBF1. Bars = 10 μm.

ErbB3 / Calnexin ; 

PubMed: 21576364     


293T cells transfected with ErbB3 were treated without (top) or with (bottom) BfA, and confocal immunofluorescence microscopy was used to examine the colocalization of ErbB3 with endogenous calnexin.

FMNL1 / GM130 ; 

PubMed: 21868368     


FMNL1 colocalizes with the cis-Golgi marker GM130 and is dispersed by treatment with brefeldin A (+BFA).

26267806 21576364 21868368
Growth inhibition assay
Cell viability; 

PubMed: 28462831     


Effects of brefeldin A on human prostate cancer cells. LNCaP and PC-3 cells were seeded in cell culture dishes and incubated for 24 h. The cells were then treated with different concentrations of brefeldin A for 72 h. The number of viable cells was determined by the trypan blue exclusion assay. Apoptosis was determined by propidium iodide staining and morphological assessment.

28462831

Protocol

Cell Research:

[5]

- Collapse
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A
Smiles CC1CCC/C=C/C2CC(O)CC2C(O)/C=C/C(=O)O1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID